14 mayo 2015
A head-to-head comparison of two biologic therapies used to treat a subset of patients with advanced kidney cancers provides much-needed clarity on the preferred treatment for the first line of attack. Research focused on three forms of non-clear cell kidney cancers: metastatic papillary, chromophobe or unclassified. The patients were randomly assigned to receive one of the two approved treatments that are typically used, everolimus or sunitinib, until their tumors progressed.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/EnxlTKRoumI/150514141012.htm
